Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
VKTX Price/Volume Stats
Current price | $32.29 | 52-week high | $99.41 |
Prev. close | $29.26 | 52-week low | $28.64 |
Day low | $28.90 | Volume | 8,638,420 |
Day high | $34.37 | Avg. volume | 4,105,569 |
50-day MA | $38.10 | Dividend yield | N/A |
200-day MA | $54.94 | Market Cap | 3.60B |
VKTX Stock Price Chart Interactive Chart >
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
VKTX Price Returns
1-mo | N/A |
3-mo | -37.46% |
6-mo | -50.04% |
1-year | -9.65% |
3-year | 849.71% |
5-year | 365.95% |
YTD | -19.76% |
2024 | 116.23% |
2023 | 97.98% |
2022 | 104.35% |
2021 | -18.29% |
2020 | -29.80% |
Loading social stream, please wait...